University of Michigan researchers argue that while gene editing could replace lifelong cholesterol medication, permanent genetic changes and high costs pose significant hurdles for widespread adoption.
Researchers at UC San Diego identified a new biological pathway causing LDL receptor loss. An existing drug candidate may soon be tested for high cholesterol treatment.